Oxidation of Methamphetamine and Methylenedioxymethamphetamine by CYP2D6

• Published in: Drug metabolism and disposition Vol. 25; no. 9; pp. 1059 - 1064
• Main Authors: LIN, L. Y, DI STEFANO, E. W, SCHMITZ, D. A, HSU, L, ELLIS, S. W, LENNARD, M. S, TUCKER, G. T, CHO, A. K
• Format: Journal Article
• Language: English
• Published: Bethesda, MD American Society for Pharmacology and Experimental Therapeutics 01.09.1997
• Subjects: Biological and medical sciences; Cytochrome P-450 CYP2D6 - metabolism; Drug addictions; Humans; Medical sciences; Methamphetamine - metabolism; Microsomes, Liver - metabolism; N-Methyl-3,4-methylenedioxyamphetamine - metabolism; Oxidation-Reduction; Saccharomyces cerevisiae; Toxicology; Amphetamine derivatives; Human; Human origin; Unspecific monooxygenase; CNS stimulant; Enzyme; Isozyme; Psychotropic; Cytochrome P450; Liver; Metamfetamine; Metabolism toxicity relation; Microsome; Metabolism; In vitro; Enzymatic activity; Toxicogenetics; Drug-metabolizing enzyme; Hydroxylator phenotype; Drug of abuse; Oxidoreductases; Recombinant protein
• ISSN: 0090-9556; 1521-009X

Methamphetamine (MeAmp) abuse has recently experienced a resurgence and approaches to the treatment of its addiction similar to those used with cocaine have been considered. As the treatment regimes are likely to use drugs whose metabolism is related to that of MeAmp, studies were initiated to establish the enzymology of the fate of MeAmp. This report describes investigations of the role of CYP2D6, the human isoform of the enzyme that catalyzes debrisoquine hydroxylation, in the 4-hydroxylation and N -demethylation of MeAmp. The results of studies with human liver microsomes including those from a genetically poor metabolizer with respect to CYP2D6, showing correlation between MeAmp and metoprolol hydroxylation and MDMA demethylenation, were consistent with a major involvement of CYP2D6 in the aromatic 4-hydroxylation of MeAmp. This was confirmed by studies with recombinant CYP2D6 expressed in yeast, which was also shown to effect the N -demethylation of MeAmp. The rate of the 4-hydroxylation reaction was substantially slower than the demethylenation of MDMA. In contrast to MeAmp, MDMA was not N -demethylated by CYP2D6. Since CYP2D6 participates in the major steps of MeAmp metabolism, pharmacokinetic interactions are likely with other drug substrates proposed for the treatment of MeAmp addiction. Furthermore, the genetic polymorphism associated with the enzyme could manifest itself in abnormal responses to MeAmp.